Alfuzosin HCl - CAS 81403-68-1
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alfuzosin HCl
Catalog Number:
81403-68-1
CAS Number:
81403-68-1
Description:
Alfuzosin HCl is an alpha1 receptor antagonist used to treat benign prostatic hyperplasia (BPH).
Molecular Weight:
425.91
Molecular Formula:
C19H28ClN5O4
COA:
Inquire
MSDS:
Inquire
Targets:
Adrenergic Receptor
Chemical Structure
CAS 81403-68-1 Alfuzosin HCl

Related Adrenergic Receptor Products


CAS 2315-02-8 Oxymetazoline Hydrochloride

Oxymetazoline Hydrochloride
(CAS: 2315-02-8)

Oxymetazoline is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant, used in the form of Oxymetazoline hydrochloride, in products such...

CAS 63659-18-7 Betaxolol

Betaxolol
(CAS: 63659-18-7)

Betaxolol is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.

CAS 86347-15-1 Medetomidine HCl

Medetomidine HCl
(CAS: 86347-15-1)

Medetomidine is a selective α2-adrenoceptor agonist, with Ki of 1.08 nM, exhibts 1620-fold selectivity over α1-adrenoceptor.

CAS 148849-67-6 Ivabradine HCl

Ivabradine HCl
(CAS: 148849-67-6)

Ivabradine HCl, a new If inhibitor with IC 50 of 2.9 μM which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering ...

Aptazapine maleate
(CAS: 71576-41-5)

Aptazapine is a tetracyclic antidepressant. It was assayed in clinical trials for the treatment of depression in the 1980s but was never marketed. Aptazapine is...

CAS 829-74-3 Levonordefrin

Levonordefrin
(CAS: 829-74-3)

Levonordefrin is a adrenergic receptor agonist and can be used as a topical nasal decongestant and vasoconstrictor in dentistry in the United States. Levonordef...

CAS 1491-59-4 Oxymetazoline

Oxymetazoline
(CAS: 1491-59-4)

Oxymetazoline, an imidazol derivative, has been found to be an adrenergic receptor agonist that could be an effective topical decongestant.

CAS 86347-14-0 Medetomidine

Medetomidine
(CAS: 86347-14-0)

Medetomidine is a potent, highly selective α2-adrenoceptor agonist, which Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively. It is often ...

Garomefrine hydrochloride
(CAS: 137431-04-0)

Garomefrine hydrochloride is a Alpha 1A adrenergic receptor agonist under the development of Nippon Shinyaku. Phase II clinical trials for the treatment of Stre...

MK-0634
(CAS: 211031-01-5)

MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s...

CAS 964-52-3 Moxisylyte hydrochloride

Moxisylyte hydrochloride
(CAS: 964-52-3)

Moxisylyte hydrochloride is alpha 1-adrenoceptor antagonist. It can vasodilates cerebral vessels without reducing blood pressure. It is used as peripheral vasod...

CAS 43229-80-7 Formoterol Hemifumarate

Formoterol Hemifumarate
(CAS: 43229-80-7)

Formoterol Hemifumarate is a potent, selective and long-acting β2-adrenoceptor agonist to β2 and β1 receptors with pKd of 8.12 and 5.58, respectively.

CAS 54765-26-3 Lerimazoline

Lerimazoline
(CAS: 54765-26-3)

Lerimazoline is an α-adrenergic receptor agonist. It inhibits secretion of nasal mucus. It causes hypertension. It is common used in the form of hydrochloride.

MK-467
(CAS: 130466-38-5)

MK-467 is a peripheral Alpha2 -adrenoceptor antagonist originated by Merck & Co. It can dose-dependently attenuate the bradycardia associated with dexmedetomidi...

CAS 5874-97-5 Metaproterenol hemisulfate salt

Metaproterenol hemisulfate salt
(CAS: 5874-97-5)

Metaproterenol hemisulfate salt is the hemisulfate salt form of Metaproterenol, which is a moderately selective beta-adrenergic agonist. It is used in the treat...

CAS 116209-55-3 Levobetaxolol HCl

Levobetaxolol HCl
(CAS: 116209-55-3)

Levobetaxolol exhibits a higher affinity at cloned human β1 and β2 receptors with Ki value of 0.76 nM and 32.6 nM, respectively.

CAS 312753-06-3 Indacaterol

Indacaterol
(CAS: 312753-06-3)

Indacaterol Maleate is an ultra-long-acting β-adrenoceptor agonist.

MK-351 hydrochloride
(CAS: 884-39-9)

MK-351 hydrochloride is an alpha-adrenergic agonist selective for α2-adrenergic receptors. It is a psychoactive drug used as a sympatholytic or antihypertensive...

CAS 849-55-8 Nylidrin hydrochloride

Nylidrin hydrochloride
(CAS: 849-55-8)

Nylidrin hydrochloride is a beta-adrenergic agonist. It was an effective inhibitor of IgE-mediated release of histamine from passively sensitized rat peritoneal...

CAS 3506-09-0 Propranolol Hydrochloride

Propranolol Hydrochloride
(CAS: 3506-09-0)

Propranolol Hydrochloride is a β-adrenergic antagonist used to treat high blood pressure, a number of types of irregular heart rate, thyrotoxicosis, capillary h...

Reference Reading


1.Kinetic Spectrophotometric Methods for the Determination of Alfuzosin Hydrochloride in Bulk and Pharmaceutical Formulations1
Salma A. AlTamimi, Fatma A. Aly, and Adibah M. Almutairi. Journal of Analytical Chemistry, 2013, Vol. 68, No. 4, pp. 313–320
The aim of the present work was to develop simple and sensitive kinetic spectrophotometric methods for the determination of alfuzosin HCl in bulk and in its pharmaceutical preparations using alkaline potassium permanganate as an oxidizing agent. The methods involve determination of alfuzosin HCl by kinetic studies of its oxidation at room temperature for a fixed time of 15 min. The absorbance of the colored manganate ions was measured at 610 nm. Alternatively, the decrease in the absorbance of permanganate upon addition of the studied drug was also measured at 525 nm. The methods were successfully applied to the determination of this drug in its dosage forms.
2.Alfuzosin: a clinically uroselective a1-blocker
Klaus Hofner, Udo Jonas. World J Urol (2002) 19: 405–412
Recently, a once-daily (o.d.) formulation of alfuzosin has been developed to improve the treatment compliance and optimise the pharmacokinetic coverage over a 24-h period. To achieve these goals, an innovative extended-release formulation, based on the Geomatrix technology(Geomatrix is a registered trademark of Jagotec AG, a member of SkyePharma Group of Companies), was used. It consists of a white hydrophilic active matrix core containing alfuzosin and two yellow inert layers, one swellable and one erodible, whose functions are to control the hydration and swelling rate of the core, leading to a controlled release of alfuzosin over the dosing interval (Fig. 3). As aqueous fluids progressively penetrate the matrix core, alfuzosin is released through a process of diffusion. Simultaneously, the swellable layer swells at a predetermined rate, increasing the surface area and the volume of the tablet to permit a slow and constant release of alfuzosin in the upper part of the digestive tract. Finally, the erodible layer dissolves with time in the lower part of the digestive tract, which allows a constant dissolution rate of alfuzosin to be maintained as the concentration decreases in the active matrix core.
3.The efficacy of Alfuzosin treatment in patients with prostatism
M. Murad Basar, Ali Atan, Osmanzergin & Mslm Yldz. International Urology and Nephrology 33: 493–497, 2001
The tone of the smooth muscle of the prostate, bladder neck and prostatic urethra is regulated by sympathetic innervation via alpha-1 adrenoceptors. Alpha-1 adrenoceptor blockers decrease the tone of the smooth muscle in the prostatic stroma, prostatic capsule, bladder neck and prostatic urethra, resulting in improving irritative and obstructive symptoms of BPH and increasing urine flow rate. Caine et al. first reported the therapeutic application of the alpha blockage for the treatment of BPH. Although Kirby et al. claimed that symptomatic improvement is generally evident in 60 to 80% of patients receiving alpha adrenocpetor blocker treatment and improvement in symptoms and urodynamic parameters are observed within 2 to 4 weeks after the treatment, Jardin et al. reported that clinical improvement with alfuzosin treatment was apparent after 6 weeks whereas peak flow rate increased and postvoiding residual urine volume decreased by 6 months. Buzelin et al. found that improvement in symptoms was significant after 1 month of the treatment and continued to improve further between weeks 4 and 12 of alfuzosin treatment. In the present study, symptomatic improvement initiated in the 2nd week of the treatment, reaching its maximum level in the 6th week whereas improvement in urodynamic parameters was obtained later than symptomatic improvement.
4.Effects of alfuzosin with methylprednisolone for spontaneous expulsion and pain control of lower ureteral stone
Eu Chang Hwang • In Sang Hwang • Ho Song Yu • Sun-Ouck Kim. Urol Res (2012) 40:605–609
Compared to tamsulosin, alfuzosin exhibits no pharmacological uroselectivity for any of the a1 subtypes (a1A, a1B, and a1D), however, alfuzosin has the lack of adverse effect and blood pressure changes, it has been claimed to be uroselective drug. Thus, it is expected to have the same effect in promoting the spontaneous stone passage. However, this is unclear, given the paucity of studies to date. Also, studies concerning the influence of corticosteroids on stone passage have mainly involved combinations with tamsulosin. Therefore, we investigated the effect of combination therapy with alfuzosin and methylprednisolone on spontaneous passage of lower ureteral stones.